Quick Answer
Allarity Therapeutics, Inc. reported Diluted EPS of $10.26 per share (loss) for fiscal year 2023.
Allarity Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2023 | -$10.26 | +99.7% |
| 2022 | -$3093.42 | -73728.6% |
| 2021 | -$4.19 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | -$0.11 | +100.0% | +99.5% |
| March 31, 2024 | -$22.14 | +99.7% | -990.6% |
| September 30, 2023 | -$2.03 | +99.8% | +99.6% |
| June 30, 2023 | -$525.53 | -875.0% | +91.7% |
| March 31, 2023 | -$6356.06 | -32262.8% | -580.3% |
| September 30, 2022 | -$934.29 | -549482.4% | -1633.4% |
| June 30, 2022 | -$53.90 | -4890.7% | -174.4% |
| March 31, 2022 | -$19.64 | — | -11452.9% |
- Allarity Therapeutics, Inc. showed an increase of +99.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2023 period, Allarity Therapeutics, Inc.’s diluted eps has declined by 144.9% (from $4.19 per share (loss) to $10.26 per share (loss)).
- The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 8, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: